245 related articles for article (PubMed ID: 25228339)
1. Discovery of new non-steroidal farnesoid X receptor modulators through 3D shape similarity search and structure-based virtual screening.
Wang L; Si P; Sheng Y; Chen Y; Wan P; Shen X; Tang Y; Chen L; Li W
Chem Biol Drug Des; 2015 Apr; 85(4):481-7. PubMed ID: 25228339
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.
Fu J; Si P; Zheng M; Chen L; Shen X; Tang Y; Li W
Bioorg Med Chem Lett; 2012 Nov; 22(22):6848-53. PubMed ID: 23040732
[TBL] [Abstract][Full Text] [Related]
3. Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR).
Merk D; Gabler M; Gomez RC; Flesch D; Hanke T; Kaiser A; Lamers C; Werz O; Schneider G; Schubert-Zsilavecz M
Bioorg Med Chem; 2014 Apr; 22(8):2447-60. PubMed ID: 24685112
[TBL] [Abstract][Full Text] [Related]
4. Farnesoid X receptor: from medicinal chemistry to clinical applications.
Fiorucci S; Mencarelli A; Distrutti E; Zampella A
Future Med Chem; 2012 May; 4(7):877-91. PubMed ID: 22571613
[TBL] [Abstract][Full Text] [Related]
5. Fragmentation of GW4064 led to a highly potent partial farnesoid X receptor agonist with improved drug-like properties.
Flesch D; Gabler M; Lill A; Gomez RC; Steri R; Schneider G; Stark H; Schubert-Zsilavecz M; Merk D
Bioorg Med Chem; 2015 Jul; 23(13):3490-8. PubMed ID: 25934227
[TBL] [Abstract][Full Text] [Related]
6. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay.
Han KC; Kim JH; Kim KH; Kim EE; Seo JH; Yang EG
Anal Biochem; 2010 Mar; 398(2):185-90. PubMed ID: 19913492
[TBL] [Abstract][Full Text] [Related]
7. Pyrazolidine-3,5-dione derivatives as potent non-steroidal agonists of farnesoid X receptor: virtual screening, synthesis, and biological evaluation.
Deng G; Li W; Shen J; Jiang H; Chen K; Liu H
Bioorg Med Chem Lett; 2008 Oct; 18(20):5497-502. PubMed ID: 18815030
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Farnesoid X Receptor Antagonists Based on a Library of Oleanolic Acid 3-O-Esters through Diverse Substituent Design and Molecular Docking Methods.
Wang SR; Xu T; Deng K; Wong CW; Liu J; Fang WS
Molecules; 2017 Apr; 22(5):. PubMed ID: 28445411
[TBL] [Abstract][Full Text] [Related]
9. Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.
Merk D; Steinhilber D; Schubert-Zsilavecz M
Future Med Chem; 2012 May; 4(8):1015-36. PubMed ID: 22650242
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
Kainuma M; Makishima M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2007 Apr; 15(7):2587-600. PubMed ID: 17292610
[TBL] [Abstract][Full Text] [Related]
11. Conformational modulation of the farnesoid X receptor by prenylflavonoids: Insights from hydrogen deuterium exchange mass spectrometry (HDX-MS), fluorescence titration and molecular docking studies.
Yang L; Broderick D; Campbell Y; Gombart AF; Stevens JF; Jiang Y; Hsu VL; Bisson WH; Maier CS
Biochim Biophys Acta; 2016 Dec; 1864(12):1667-1677. PubMed ID: 27596062
[TBL] [Abstract][Full Text] [Related]
12. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
[TBL] [Abstract][Full Text] [Related]
13. Pyrazole[3,4-e][1,4]thiazepin-7-one derivatives as a novel class of Farnesoid X Receptor (FXR) agonists.
Marinozzi M; Carotti A; Sansone E; Macchiarulo A; Rosatelli E; Sardella R; Natalini B; Rizzo G; Adorini L; Passeri D; De Franco F; Pruzanski M; Pellicciari R
Bioorg Med Chem; 2012 Jun; 20(11):3429-45. PubMed ID: 22564381
[TBL] [Abstract][Full Text] [Related]
14. SAR studies on FXR modulators led to the discovery of the first combined FXR antagonistic/TGR5 agonistic compound.
Lamers C; Merk D; Gabler M; Flesch D; Kaiser A; Schubert-Zsilavecz M
Future Med Chem; 2016; 8(2):133-48. PubMed ID: 26824277
[TBL] [Abstract][Full Text] [Related]
15. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
Festa C; Renga B; D'Amore C; Sepe V; Finamore C; De Marino S; Carino A; Cipriani S; Monti MC; Zampella A; Fiorucci S
J Med Chem; 2014 Oct; 57(20):8477-95. PubMed ID: 25247751
[TBL] [Abstract][Full Text] [Related]
16. Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.
Selwa E; Elisée E; Zavala A; Iorga BI
J Comput Aided Mol Des; 2018 Jan; 32(1):273-286. PubMed ID: 28865056
[TBL] [Abstract][Full Text] [Related]
17. Transactivation and Coactivator Recruitment Assays for Measuring Farnesoid X Receptor Activity.
Hsu CW; Zhao J; Xia M
Methods Mol Biol; 2016; 1473():43-53. PubMed ID: 27518622
[TBL] [Abstract][Full Text] [Related]
18. Enrichment assessment of multiple virtual screening strategies for Toll-like receptor 8 agonists based on a maximal unbiased benchmarking data set.
Pei F; Jin H; Zhou X; Xia J; Sun L; Liu Z; Zhang L
Chem Biol Drug Des; 2015 Nov; 86(5):1226-41. PubMed ID: 26017460
[TBL] [Abstract][Full Text] [Related]
19. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
Sindhu T; Srinivasan P
Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
[TBL] [Abstract][Full Text] [Related]
20. Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2.
Athanasiou C; Vasilakaki S; Dellis D; Cournia Z
J Comput Aided Mol Des; 2018 Jan; 32(1):21-44. PubMed ID: 29119352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
